K O R E A N V A C C I N E S O C I E T Y K O R E A N A C C I N E O C I E T Y V S
http://www.ecevr.org/ Seoul, 2011 . Seoul was the city with the fourth greatest number of clinical trials that were conducted worldwide in 2011, which was followed by Berlin in German and Houston and New York in US.
The outcome has been driven from win-win strategy through R & D investment that pharmaceutical companies have seek to gain a competitive advantage and with stably secured investment consistent with the needs of the hospitals to perpetuate diverse and profound research. Ensuring a stable supply of NIP vaccines, KFDA has planned to expand from vaccines for eleven different types of diseases to them for twenty-two infectious diseases, which produced from domestic manufactures by 2017.
Only six out of twelve in the list of NIP could be produced in domestic manufactures in Korea. KFDA will support to expand six to eleven kinds of vaccines by 2017.
-NIP: Vaccines for varicella-zoster virus, typhoid fever, hepatitis B, etc., which administrated from community health centers and hospital settings and covered by national health insurance program -Othe rs: Vaccines for hepatitis A, pneumonia, etc., which not covered by national health insurance program More clinical trials will be accompanied by the action plan, "Ensuring a stable supply of NIP vaccines. " Based on excellent clinical research infrastructure and medical researchers, pharmaceutical industry in Korea will be strengthened in the global pharmaceutical market. The paradigm shift towards integrated and preventive healthcare will be coordinated to invest R & D for vaccines and progressively to expand the market of vaccine industry.
KFDA has made efforts to provide technical support on construction and relocation of manufacture. KFDA will also improve any burdensome of regulatory obstacles over the whole life cycle of a product to expedite marketing through consultative groups with pharmaceutical cooperatives. KFDA enables domestic manufactures to expand overseas marketing opportunities by achieving the international competitiveness with human infrastructure and World Health Organization collaboration. KFDA has established lot release procedures of vaccines to assure the consistent quality of each manufactured lot. Therefore, it will strengthen the regulatory system as a part of the whole regulatory framework which includes marketing authorization, good manufacturing practices inspection, and post marketing surveillance, etc. Against this backdrop, KFDA will support the vaccine development and promote excellent public health protection by integrating regulatory systems. 
